Hepatitis C Screening, Prevalence and Drug Effectiveness
Hepatitis C is a liver disease caused by infection with the hepatitis C virus. Severity can range from a mild illness lasting a few weeks to a lifelong serious illness. Hepatitis C is usually spread when blood from a person infected with the hepatitis C virus enters the body of someone who is not infected. Many people with hepatitis C virus do not know they are infected, so efforts are underway to increase rates of screening so that people can be treated.
Screening and prevalence for Veterans in VA care
Hepatitis C screening and infection rates for Veterans who received VA care in calendar year (CY) 2012 and in (CY) 2013 were significantly higher for Veterans born from 1945-65 than those born in other periods.
- American Journal of Public Health 2014: Impact of Race/Ethnicity and Gender on HCV Screening and Prevalence Among U.S. Veterans in Department of Veterans Affairs Care
- American Association for the Study of Liver Diseases (AASLD) 2013 Abstract HCV Screening and Prevalence in VA in CY 2012 (Scroll to Abstract 21)
- AASLD 2013 Oral presentation HCV Screening and Prevalence in VA in CY 2012 (585 KB, PDF)
- AASLD 2013 One slide summary HCV Screening and Prevalence in VA in CY 2012 (125 KB, PDF)
- Journal of the American Medicine Association (JAMA) IM Research Letter CY 2013 Rates of Hepatitis C Virus Testing in VA
- American Public Health Association (APHA) 2013 Abstract HCV Screening and Prevalence in VA Facilities CY 2011
- APHA 2013 Poster HCV Screening and Prevalence in VA Facilities in CY 2011 (66 KB, PDF)
Effectiveness of sofosbuvir-based therapy
This project describes the sustained virologic response in Veteran’s starting SOF-based therapy in 2014.
- Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans
Comparative effectiveness of boceprevir and telaprevir-based therapy
This project compared the effectiveness of two hepatitis C drugs, boceprevir and telaprevir, prescribed to 859 U.S. Veterans starting in 2011. The chance of sustained virologic response (SVR) - thought to be a cure - was higher for Veterans on telaprevir.
- AASLD 2013 Abstract Comparative Effectiveness of Boceprevir and Telaprevir (Scroll to Abstract 1848)
- AASLD 2013 Comparative Effectiveness of Boceprevir and Telaprevir (98 KB, PDF)
- Alimentary Pharmacology and Therapeutics (AP&T) 2013 Article Comparative Effectiveness of Boceprevir and Telaprevir
Population Approach to Direct Acting Antivirals
This project describes the comprehensive program established by VA to oversee the use of the new direct-acting antivirals.
- A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System
This program includes critical analysis of the differences between clinical efficacy observed in clinical trials and clinical effectiveness observed in clinical practice.
Download free viewer and reader software to view PDF, video and other file formats.